Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 10:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,976 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Test Product Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants

NCT03131895
View directory record Official record
Conditions
Healthy Volunteers
Interventions
30 mg dexlansoprazole capsules manufactured at TOB, 30 mg dexlansoprazole capsules manufactured at TPC, 60 mg dexlansoprazole capsules manufactured at TOB, 60 mg dexlansoprazole capsules manufactured at TPC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 17, 2026, 10:34 PM EDT
Recruiting Phase 1Phase 2 Interventional

Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).

NCT06159166
View directory record Official record
Conditions
NF1, Cutaneous Neurofibroma, Monotherapy
Interventions
Mirdametinib
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 17, 2026, 10:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Controlled-Release Oxycodone Hydrochloride 40 mg Tablets and OxyContin® 40 mg Tablets

NCT00853892
View directory record Official record
Conditions
Healthy
Interventions
Controlled-Release Oxycodone Hydrochloride 40 mg tablet, OxyContin® 40 mg tablet
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Oct 17, 2026, 10:34 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Oxytocin as Adjunctive Treatment of Schizophrenia

NCT01568528
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin, Placebo, Control
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 17, 2026, 10:34 PM EDT
Completed Not applicable Interventional Results available

A Clinical Investigation Evaluating and Understanding Parameters Affecting the Performance of Ostomy Products

NCT02517541
View directory record Official record
Conditions
Ileostomy - Stoma, Colostomy
Interventions
SenSura Mio Convex Soft
Device
Lead sponsor
Coloplast A/S
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Chicago, Illinois • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Oct 17, 2026, 10:34 PM EDT
Withdrawn Phase 2 Interventional

A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation

NCT06297629
View directory record Official record
Conditions
Allogeneic Stem Cell Transplantation
Interventions
ASTX727, Donor Lymphocyte Infusion
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 17, 2026, 10:34 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

COvid-19 LongitUdinal Multiethnic BioImaging Assessment of CARDiovascular Sequelae Registry

NCT04661657
View directory record Official record
Conditions
Covid19, Cardiac Disease, Cardiac Arrhythmia, Myocarditis, Left Ventricular Dysfunction
Interventions
Transthoracic echocardiogram (TTE), Cardiovascular Magnetic Resonance (CMR) Imaging
Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Oct 17, 2026, 10:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE)

NCT04134767
View directory record Official record
Conditions
Substance Use, HIV Infections, HCV Infection, Sexually Transmitted Infections (Not HIV or Hepatitis), Overdose, Drug, Opioid Use
Interventions
Health Linkage, Overdose Education
Behavioral
Lead sponsor
April M Young
Other
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 17, 2026, 10:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371

NCT03199339
View directory record Official record
Conditions
Tuberculosis, Tuberculosis, Pulmonary
Interventions
TBA-7371, Placebo
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 17, 2026, 10:34 PM EDT
Completed Phase 1 Interventional Results available

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

NCT02595866
View directory record Official record
Conditions
AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma, HIV Infection, Kaposi Sarcoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma, Recurrent Malignant Neoplasm, Refractory Classic Hodgkin Lymphoma, Refractory Malignant Neoplasm, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Melanoma
Interventions
Antiretroviral Therapy, Biopsy, Biospecimen Collection, Computed Tomography, Pembrolizumab, Positron Emission Tomography
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 17, 2026, 10:34 PM EDT
Completed Phase 2 Interventional Results available

Prescription Opioid Abuse Among Pain Patients: Predictors of Relapse

NCT01967641
View directory record Official record
Conditions
Opioid Dependence
Interventions
buprenorphine/naloxone combination
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 17, 2026, 10:34 PM EDT
Completed Phase 3 Interventional

ACTIV-3: Therapeutics for Inpatients With COVID-19

NCT04501978
View directory record Official record
Conditions
Covid19
Interventions
LY3819253, Placebo, Remdesivir, VIR-7831, BRII-196/BRII-198, AZD7442, MP0420, PF-07304814
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
2,753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
98
States / cities
Tucson, Arizona • Chula Vista, California • Fresno, California + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 17, 2026, 10:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study of Advil Dual Action Liquid Filled Capsules (125 mg/250 mg) Versus Advil Dual Action Caplets (125 mg/250 mg) and Bioavailability Assessment of Advil Dual Action Liquid Filled Capsules (125 mg/250 mg) and Advil Liqui-Gels (200 mg) in Healthy Adult Subjects

NCT06802185
View directory record Official record
Conditions
Pain
Interventions
ADA Liquid Filled Capsules (Test Product), ADA Caplets (Reference Product), Advil Liqui-gels (Reference Product)
Drug
Lead sponsor
HALEON
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 17, 2026, 10:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Effects of Omeprazole on the Pharmacokinetics of XS004 (Dasatinib) Tablets in Healthy Adult Subjects Under Fasting Conditions

NCT05433896
View directory record Official record
Conditions
Pharmacokinetics, Drug Interactions
Interventions
Dasatinib ASD, Omeprazole 40 MG
Drug
Lead sponsor
Xspray Pharma AB
Industry
Eligibility
18 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Dilworth, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Oct 17, 2026, 10:34 PM EDT
Terminated Phase 3 Interventional Results available

Clinical Equivalence Study of Fluticasone Propionate Nasal Spray, 50 mcg/Actuation vs. Flonase in Allergic Rhinitis Patients

NCT02246920
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Fluticasone propionate, Flonase®, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
12 Years and older
Enrollment
1,474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 17, 2026, 10:34 PM EDT
Recruiting Phase 3 Interventional

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

NCT07388524
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma
Interventions
Atezolizumab, Atezolizumab and Recombinant Human Hyaluronidase, Biospecimen Collection, Computed Tomography, Patient Observation
Biological · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
100
States / cities
Beverly Hills, California • Los Angeles, California • Tarzana, California + 83 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 10:34 PM EDT
Completed Phase 3 Interventional Results available

To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes

NCT04944290
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Brinzolamide/brimonidine ophthalmic suspension, Simbrinza 0.2%/1% Ophthalmic Suspension
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
18 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 17, 2026, 10:34 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Mechanistic Evaluation of Polypharmacy Effects for Pain

NCT07846020
View directory record Official record
Conditions
Chronic Lower Back Pain (CLBP)
Interventions
Within-subject test of blinded study medications (Placebo, Hydromorphone, Gabapentin)
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 17, 2026, 10:34 PM EDT
Completed Not applicable Interventional

Tolerability Study of Panosyl Isomaltooligosaccharides (PIMO), in Subjects With Chronic Idiopathic Constipation (CIC)

NCT05129618
View directory record Official record
Conditions
Constipation Chronic Idiopathic
Interventions
MHS 1031, placebo
Dietary Supplement · Other
Lead sponsor
Microbiome Health Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Manassas, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Oct 17, 2026, 10:34 PM EDT
Recruiting Phase 3 Interventional

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

NCT07198074
View directory record Official record
Conditions
Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma
Interventions
Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
303
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 226 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 17, 2026, 10:34 PM EDT
Completed Not applicable Interventional

Open-Label Study of Omega 3 Oil Supplementation for Aging-Related Cognitive Decline

NCT04484454
View directory record Official record
Conditions
Cognitive Decline
Interventions
ProdromeNeuro Omega 3 Oil Nutritional Supplement
Dietary Supplement
Lead sponsor
Neurological Associates of West Los Angeles
Other
Eligibility
35 Years to 65 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Oct 17, 2026, 10:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study of LY3154207 in Healthy Participants

NCT03942029
View directory record Official record
Conditions
Healthy
Interventions
LY3154207 Capsule, LY3154207 Tablet, Placebo, Fluconazole Tablet
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 17, 2026, 10:34 PM EDT
Completed Phase 2 Interventional Results available

Fentanyl Pectin Nasal Spray (FNPS) for Exercise-Induced Breakthrough Dyspnea

NCT01832402
View directory record Official record
Conditions
Advanced Cancers
Interventions
Fentanyl Pectin Nasal Spray, Placebo Nasal Spray, Walk Test, Questionnaires, Mental Ability Tests
Drug · Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 17, 2026, 10:34 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Generic Diclofenac Epolamine Acute Pain Due to Minor Ankle Sprain

NCT02324270
View directory record Official record
Conditions
Ankle Sprain
Interventions
Diclofenac epolamine, Placebo
Drug · Other
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
658 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
31
States / cities
Birmingham, Alabama • Goodyear, Arizona • Carlsbad, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2020 · Synced Oct 17, 2026, 10:34 PM EDT